Location · DuBois, PA
Clinical trials in DuBois, PA
22 recruiting studies have a site in DuBois, and 0 of them accept healthy volunteers.
22 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
AstraZeneca
- Location
- DuBois, PA + 58 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 3
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
PureTech
- Location
- DuBois, PA + 15 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
Windward Bio
- Location
- DuBois, PA + 8 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2/Phase 3
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Pfizer
- Location
- DuBois, PA + 58 other US sites
- Eligibility basics
- Ages 35–80
- RecruitingPhase 2
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
Altesa Biosciences, Inc.
- Location
- DuBois, PA + 28 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 4
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Sanofi
- Location
- DuBois, PA + 10 other US sites
- Eligibility basics
- Ages 40–85
- Recruiting
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Apreo Health, Inc.
- Location
- DuBois, PA + 17 other US sites
- Eligibility basics
- Ages 40–84
- RecruitingPhase 2
Study of ORJ-001 for the Treatment of IPF
Oorja Bio, Inc.
- Location
- DuBois, PA + 1 other US site
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Pfizer
- Location
- DuBois, PA + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
AstraZeneca
- Location
- DuBois, PA + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Trevi Therapeutics
- Location
- DuBois, PA + 21 other US sites
- Eligibility basics
- Ages 40+
- RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
UCB Biopharma SRL
- Location
- DuBois, PA + 6 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Eli Lilly and Company
- Location
- DuBois, PA + 13 other US sites
- Eligibility basics
- Ages 40–75
- RecruitingPhase 3
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
GlaxoSmithKline
- Location
- DuBois, PA + 50 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Expedition Therapeutics, Inc
- Location
- DuBois, PA + 21 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
UCB Biopharma SRL
- Location
- DuBois, PA + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
AstraZeneca
- Location
- DuBois, PA + 53 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
GlaxoSmithKline
- Location
- DuBois, PA + 13 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
GlaxoSmithKline
- Location
- DuBois, PA + 29 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
GlaxoSmithKline
- Location
- DuBois, PA + 37 other US sites
- Eligibility basics
- Ages 40–75
- RecruitingPhase 3
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
GlaxoSmithKline
- Location
- DuBois, PA + 7 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
Nuvaira, Inc.
- Location
- DuBois, PA + 5 other US sites
- Eligibility basics
- Ages 40–80